PTP4A3 and colorectal cancer: Interestingly, colorectal cancer cells treated with Salirasib in combination with PRL-3 shRNA had significantly reduced migration compared to control shRNA, with the scratch widening after 24 h, indicating some die-off of PRL-3 shRNA/Salirasib treated cells that is not present in the control shRNA/Salirasib treated cells (Supplemental Fig. 9).